Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Navidea Biopharmaceuticals stock opened at $0.00 on Friday. Navidea Biopharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.13. The firm has a market capitalization of $100,084.00, a price-to-earnings ratio of -0.02 and a beta of 1.45.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.